All In Biotech

Drug Trial Radar · NCT05189444

The Evaluation of Triple Therapy With Vonoprazan, Amoxicillin and Bismuth for Eradication of Helicobacter Pylori

The Evaluation of Triple Therapy With Vonoprazan, Amoxicillin and Bismuth for Eradication of Helicobacter Pylori: a Prospective, Multi-Center, Randomized Controlled Trial

Last checked: Nov 20, 2026Latest source record: Mar 22, 2022 (this record)Source: ClinicalTrials.govMethods & limitations

Status unknownPivotal-lookingRandomized with 672 participants. This is a heuristic, not a regulatory label.

Status

Status unknown

Enrollment

672

Planned (sponsor's estimate)

Start

Mar 25, 2022

Primary completion

Dec 31, 2022

Study completion Dec 31, 2022

Sponsor

Lead sponsor
Huazhong University of Science and TechnologyAcademic, hospital or other
Sponsor type
Academic, hospital or other
First posted
Jan 12, 2022

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Not applicable
Allocation
Randomized
Model
Parallel
Masking
None
Primary purpose
Treatment
FDA-regulated drug
No
Who can join
All sexes, from 18 years, up to 65 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The eradication rate of standard quadruple therapy has become less successful due to low compliance and high resistance to antibiotics. Therefore, it is necessary to develop new treatment strategies that increase the eradication rate and reduce adverse effects. The aim of this prospective study is to investigate the efficacy of Triple Therapy with Vonoprazan, Amoxicillin, and Bismuth for eradication of Hp, compared with standard quadruple therapy.

Conditions

  • Helicobacter Pylori Infection

Interventions

  • VonoprazanDrug

    20mg bid

  • AmoxicillinDrug

    0.75g tid

  • EsomeprazoleDrug

    20mg bid

  • AmoxicillinDrug

    1.0g bid

  • ClarithromycinDrug

    0.5g bid

  • Bismuth potassium citrateDrug

    0.22g bid

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Helicobacter pylori eradicationTime frame: 6 weeks after treatment initiation

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • Tongji Hospital, Tongji Medical College, HUST

    Wuhan, Hubei, China

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.